Tecentriq (atezolizumab)

Tecentriq (Atezolizumab) injection is a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. Tecentriq is approved either alone or in combination with targeted therapies/chemotherapies, for adult patients with various forms of metastatic non-small cell lung cancer (NSCLC), PD-L1 positive NSCLC after surgery, extensive-stage small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), and BRAF V600 mutation-positive unresectable or metastatic melanoma.

In case of any adverse events or safety queries, please contact: [email protected]

If you have a scientific query related to one of Roche's products, please contact: [email protected]